Member Info for JamYesterday

I have time wasters like this "Thorn" character on filter. It makes life much simpler.

Exactly right, Spank.

July 17th rns:

" Samples at JORC accredited laboratories - first assay results expected imminently."

Great question, cjmorley.

I suppose part of the answer revolves around whether HEX can sell small lot amounts at a local spot rate, initially, versus a more lucrative longer term secure and consistent quality supply contract, at volume, to a large industrial user.

I think what gets me the most about this latest placing with warrants is the sheer greediness of the warrant terms attached. Or is it desperation on BRES's behalf to get a rather trivial amount of money raised quickly?

Time was, back in 2023, when RAB Capital took 11% of the £636k placing then, at 5p but the warrants were exercisable at a 8p strike price and only 1/2 warrant per placing share. How different is that, with a 4p placing price and 5p exercise price, at 1 for 1!!

Seems to me that the RAB /BRES relationship is going too close for comfort, to the detriment of outside shareholders.

Sasha, take that view back to your masters.

You can buy shares in Avacta today, at 46p, at the same level as in March 2022.

Let that sink in for a moment.

In March 2022, ok, with just 254mn shares issued vs 405mn today, Avacta was about to start the second cohort of AV6000 in its Phase 1a CT, at a dose of 120mg/M2. Avacta had selected AVA3996 as the next pre|CISION pro-drug candidate "with a view" to start a first in-human Phase 1 clinical trial . CEO AS in charge, lecturing us with his fireside chats and plans to grow a dual diagnostics and therapeutics healthcare business based on the Affimer licensed tech and pre|CISION targeted chemotherapies.

How events have moved on since then, slowly (too slowly for most PIs) but surely. AS gone. Diagnostics gone. CLNs..still on the b/s but better financial acumen employed now to sort this issue out.

What a tremendous buying opportunity at every PI's feet, if you believe in the science and financial staying power of Avacta.

Get your full positions by the start of Q4 for a potentially exhillarating journey in 2026, not without risks , of course, but it should be worth the wait.

GLA and DYOR.

...and am sorry to see the value of this promising bit of healthcare tech just wither on the vine, so to speak.

But why has it behaved thus?

As a long term observer of how opinions have changed on this board, I note that AV6k is no longer viewed as a "company maker" i its own right, with near term monetisation for shareholders implied, to now being a "pathfinder" on the way to proving up the whole platform - with monetisation deferred.

I've waited this long, so can just as well wait a year or two more, but just saying.....

Not today, Clever Thoughts. I have a headache.

Oh dear. If there is a placing RNS in the morning, after the size blocks traded today, then this counter and its players really are the lowest of the low.

Today's useless bit of info:

Tavira would normally earn about a 10% commission on a placing. So on a gross £290k raised, and with 435,000 Broker warrants issued, they need a share price of 10.66p to break even versus cash payment.

Someone's very bullish, or can't be paid in cash at this time.

...or Inpex getting a move on.

The rationale for this small placing is understandable, but, why oh why issue a full 1 for 1 warrant amounting to another 7mn- odd for something like this and with a friendly large investor involved?

These Bres warrants are going to be a real millstone around its neck when the time comes to do some serious value adding with real news.

Just about time now to change the scale on the investing.com charts.

"Theyll take over 30m at 0.3p"

Show off.

That can't be right. Later on in their presentation the refer to initial production of 15mmcfd. Confusing.

Running the Avanti stated numbers, it does appear undervalued to Hex.

Total planned production of 18500mmcfd at 1.1% He from the two Sawgrass wells. MC of Avanti just C$16mn.

Porters, that's because it's all been a cunning plan all along.

Sorry, my mistake. SVN001 is already in P3 in the UK.

Has Svns made any public statements about the expected cost of the P3 trial and how it will fund this?

Seems that warrant exercises are likely to be a continuing supply issue for SVNS in the next while. Apart from that, the fundamental story is solid.